Antilipemic Agents
Research News and Information

Sunday, November 22, 2009

Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.

Nov 2009 OBJECTIVES: Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function. BACKGROUND: NA raises high-density lipoprotein cholesterol (HDL-C) and reduces low-density ... Read more...

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.

24 Oct 2009 BACKGROUND: The role of high-density lipoprotein cholesterol (HDL-C) as a therapeutic target to prevent cardiovascular (CV) events remains unclear. We examined data from the Framingham Offspring Study from 1975 through 2003 to determine whether ... Read more...

The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

18 Oct 2009 OBJECTIVES: We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects. BACKGROUND: Statin-induced side effects can interfere with therapy. Single nucleotide polymorphisms in cytochrome P450 enzymes impair ... Read more...

Latest indexed articles for 'Antilipemic Agents'

These are the very latest articles for this heading:

• Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging. Nov 2009
• Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. Nov 2009
• ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. 24 Oct 2009
• Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. 24 Oct 2009
• Lipoprotein(a) measurement and determining risk of myocardial infarction. 19 Oct 2009
• The SLCO1B1*5 genetic variant is associated with statin-induced side effects. 18 Oct 2009
• Acute cholestatic hepatitis induced by fenofibrate. 29 Sep 2009
• Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats. 29 Sep 2009
• 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. 29 Sep 2009
• Probing the fibrate binding specificity of rat liver fatty acid binding protein. 8 Sep 2009
• [Myopathy in the course of hypolipemic theraphy in patient undergoing early cardiac rehabilitation after the percutaneous coronary intervention--a case report] 30 Aug 2009
• Lipid lowering and aortic valve disease. 30 Aug 2009
• ApoB versus non-HDL-C: what to do when they disagree. 30 Aug 2009
• Lipid-lowering drugs and risk for cancer. 30 Aug 2009
• Ethyl-eicosapentaenoic acid reduces liver lipids and lowers plasma levels of lipids in mice fed a high-fat diet. 30 Aug 2009
• The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels. 30 Aug 2009
• Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. 30 Aug 2009
• Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. 30 Aug 2009
• Nonpharmacologic treatment of dyslipidemia. 30 Aug 2009
• Antidiabetic and antilipidemic effect of eremanthin from Costus speciosus (Koen.)Sm., in STZ-induced diabetic rats. 16 Aug 2009

See a longer list of these articles.

Technical information about 'Antilipemic Agents'

Definition: Substances used to treat HYPERLIPIDEMIAS.

Registry Number: 0

Descriptor UI: D000960

Alternative terms: Antilipemic Agents; Agents, Antilipemic; Antihyperlipidemics; Antihyperlipemics; Antilipemics; Antilipemic Drugs; Drugs, Antilipemic; Hypolipidemic Agents; Agents, Hypolipidemic;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.186.071; D27.505.954.230;

History Note: 72(66)